About Us
Our groundbreaking extraction technologies will allow us to provide unique innovations that are unmatched in the market.
Company History
Since 2019, 113 Botanicals has been developing innovative technologies for the extraction of GMP grade cannabinoid extracts for the pharmaceutical and medical markets
Using our own API extract, 113 Botanicals are focused on developing novel routes of administration. We have developed a first-in-class, controlled and sustained-release capsule technology that we believe will address significant unmet medical needs within the growing global markets.
Our Research
Our groundbreaking research and development is carried out in partnership with the renowned Life Sciences department within the University of Sussex.
We have an extensive IP portfolio which includes filed patents for both our unique extraction technologies and for our innovative formulations and routes of administration.
113 Botanicals has successfully completed the UK intellectual property office’s IP audit process to confirm validity and robustness of our IP portfolio.
Licencing And Compliance
Home Office License
EU-GMP
MHRA
